T9G Stock Overview

An investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. More details

T9G fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the German market

Does not have a meaningful market cap (€37M)

My Notes

Capture your thoughts, links and company narrative

Vidac Pharma Holding Plc Competitors

4SC

DB:VSC

€58.9m

2invest

XTRA:2INV

€68.4m

Medigene

XTRA:MDG1

€17.4m

Heidelberg Pharma

XTRA:HPHA

€118.4m

Price History & Performance

Summary of share price highs, lows and changes for Vidac Pharma Holding
Historical stock prices
Current Share Price	€0.67
52 Week High	€1.40
52 Week Low	€0.15
Beta	0
1 Month Change	6.40%
3 Month Change	-14.74%
1 Year Change	-44.58%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-57.10%

Recent updates

Shareholder Returns

	T9G	DE Biotechs	DE Market
7D	-7.0%	-2.1%	3.0%
1Y	-44.6%	-3.8%	12.8%

Return vs Industry: T9G underperformed the German Biotechs industry which returned -3.8% over the past year.

Return vs Market: T9G underperformed the German Market which returned 12.8% over the past year.

Price Volatility

Is T9G's price volatile compared to industry and market?
T9G volatility
T9G Average Weekly Movement	16.8%
Biotechs Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: T9G's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: T9G's weekly volatility has decreased from 22% to 17% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2021	n/a	n/a	www.vidacpharma.com

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors.

Vidac Pharma Holding Plc Fundamentals Summary

How do Vidac Pharma Holding's earnings and revenue compare to its market cap?
T9G fundamental statistics
Market cap	€37.17m
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is T9G overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
T9G income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did T9G perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/20 13:45
End of Day Share Price	2025/01/17 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vidac Pharma Holding Plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peter-Thilo Hasler	Sphene Capital GmbH

Vidac Pharma Holding BST:T9G Stock Report